Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRC

Johanna C. Bendell, MD
Published: Thursday, Jan 04, 2018



Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

For patients with MSI-H disease, they can still have the general standard chemotherapies that are still available to them, as well as targeted agents following progression on checkpoint inhibitor therapy, explains Bendell.

If a patient progresses on the checkpoint inhibitor, they could potentially go on to regorafenib (Stivarga), TAS-102 (Lonsurf), or a clinical trial. According to Bendell, there are many clinical trials that are looking at combinations for patients who have progressive disease following single-agent immunotherapies.
 


Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

For patients with MSI-H disease, they can still have the general standard chemotherapies that are still available to them, as well as targeted agents following progression on checkpoint inhibitor therapy, explains Bendell.

If a patient progresses on the checkpoint inhibitor, they could potentially go on to regorafenib (Stivarga), TAS-102 (Lonsurf), or a clinical trial. According to Bendell, there are many clinical trials that are looking at combinations for patients who have progressive disease following single-agent immunotherapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x